Herceptin Biosimilars Market

The Herceptin Biosimilars market consists of cost-effective, clinically equivalent versions of the biologic drug trastuzumab, used for treating HER2-positive cancers. The primary customers are healthcare systems, including hospitals, specialty clinics, and oncology centers, which seek to reduce treatment costs. Key growth drivers for this market include the expiration of the original drug's patent, supportive regulatory pathways for biosimilar approval, the rising global prevalence of HER2-positive cancers, and a strong push for cost containment in healthcare.